Publications by authors named "David Pariser"

Claim this Profile
T
The enduring impact of the American Dermatological Association on US dermatology.
Thomas N Helm, Amy S Paller, David M Pariser

J Am Acad Dermatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study.
Todd Schlesinger, M Shane Chapman, John H Tu, Joel L Cohen, John Strasswimmer, David M Pariser

J Am Acad Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.
Kim A Papp, James Q Del Rosso, Mark G Lebwohl, Melinda J Gooderham, Adelaide A Hebert, David M Pariser

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, James Q Del Rosso, Zoe D Draelos, David M Pariser

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, David M Pariser

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.
David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper

J Am Acad Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.
Bruce E Strober, Michael Bukhalo, April W Armstrong, David Pariser, Leon Kircik

Dermatol Ther (Heidelb)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
David M Pariser, Mark G Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk

Dermatol Ther (Heidelb)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.
William Coleman, Vince Bertucci, Shannon Humphrey, Joely Kaufman-Janette, Terrence Keaney, David Pariser

Aesthet Surg J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Mark G Lebwohl, John Y Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, David M Pariser

Adv Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pivotal Study on the Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating.
Stacy Smith, Dee Anna Glaser, Lawerence J Green, Micheal S Kaminer, Erin Tims, David M Pariser

Dermatol Surg· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Atopic Dermatitis Control Tool: Adaptation and Content Validation for Children and Caregivers of Children with Atopic Dermatitis.
Chien-Chia Chuang, David M Pariser, Eric Simpson, Jennifer Dine, Michelle Brown

Dermatol Ther (Heidelb)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Christos C Zouboulis, Thierry Passeron, David Pariser, Magdalena B Wozniak, Xianjun Li

Br J Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities.
Daniel Piacquadio, Brian Berman, Daniel M Siegel, Neal Bhatia, Jason Brocato, David M Pariser

J Clin Aesthet Dermatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building a Group Practice and Going Big.
David M Pariser

Dermatol Clin· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani, David M Pariser

Br J Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, David M Pariser

JAMA Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel.
Danny Zakria, Nicholas Brownstone, April W Armstrong, Erin E Boh, John Y M Koo, David Pariser

J Drugs Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Zoe D Draelos, David N Adam, H Chih-Ho Hong, Mark G Lebwohl, Charles W Lynde, David M Pariser

Br J Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-Blind, Placebo-Controlled Study of Onabotulinumtoxin A for the Treatment of Hailey-Hailey Disease.
Ryan Saal, Charlene Oldfield, James Bota, Robert Pariser, David Pariser

J Drugs Dermatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Linda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, Melinda J Gooderham, Steven E Kempers, David M Pariser

Am J Clin Dermatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Diamant Thaçi, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser

Br J Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
Andrew Blauvelt, David M Pariser, Stephen Tyring, Jerry Bagel, Andrew F Alexis

J Dermatol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
Mark Nestor, David Pariser, James Del Rosso, Dee Anna Glaser, David Goldberg

J Clin Aesthet Dermatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Future of Contract Research Organizations in Dermatology and Aesthetic Research.
Mark Nestor, David Pariser, James Del Rosso, Dee Anna Glaser, David Goldberg

J Clin Aesthet Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis